Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
Rhea-AI Summary
Certara (Nasdaq: CERT) agreed to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, with closing expected in Q2 2026 subject to customary conditions.
In 2025 the unit generated $50 million revenue and $17 million adjusted EBITDA and includes ~220 employees. Certara will update 2026 guidance upon close and intends to deploy proceeds to advance its MIDD and Clinical Intelligence strategy.
Positive
- Deal value up to $135 million
- 2025 revenue contribution: $50 million
- 2025 adjusted EBITDA contribution: $17 million
- 220 employees included in the business transfer
- Proceeds earmarked to accelerate MIDD and Clinical Intelligence
Negative
- Divestiture removes ~$50 million of annual revenue
- Certara will revise 2026 guidance after transaction close
- Transaction completion is subject to customary closing conditions
News Market Reaction – CERT
In the Apr 22 session, CERT gained 2.90%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Earnings date notice | Neutral | +2.6% | Announcement of Q1 2026 earnings release date and conference call details. |
| Mar 03 | Regulatory acceptance | Positive | +2.7% | FDA acceptance of Simcyp PBPK modeling in place of multiple clinical pharmacology trials. |
| Feb 27 | Investor conferences | Positive | +4.1% | Management participation in several March 2026 investor conferences with webcasts. |
| Feb 26 | Earnings and guidance | Positive | +3.2% | FY2025 growth, Q4 results, new CEO, and full-year 2026 guidance ranges provided. |
| Jan 29 | Earnings date notice | Neutral | -1.5% | Notification of Q4 and FY2025 earnings release timing and call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including earnings and strategic/product updates, has generally coincided with positive next-day price reactions.
Over the last few months, Certara has combined financial updates with strategic and technical milestones. FY2025 results on Feb 26, 2026 showed revenue of $418.8M and adjusted EBITDA of $134.5M, alongside 2026 guidance and a new CEO. Subsequent items included conference participation and an FDA-accepted Simcyp modeling result that replaced multiple human trials, each followed by positive price moves. Today’s divestiture of the Regulatory and Medical Writing business continues the strategic focus on core modeling and clinical intelligence offerings.
Key Terms
model-informed drug development (midd) medical
adjusted ebidta financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence
Updated 2026 guidance to be provided upon transaction close
RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to
“Certara’s strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions,” said Jon Resnick, Chief Executive Officer. “This transaction underlines our commitment to the acceleration of AI-integrated modeling and simulation across the drug development lifecycle.”
In 2025, the Regulatory and Medical Writing business generated
“This transaction enhances our ability to accelerate investment in Certara’s integrated MIDD platform for customers, while sharpening our focus on product innovation and operational excellence,” said Resnick. “Consistent with our strategy, we intend to deploy the proceeds to drive long-term value for customers, patients, and shareholders.”
Certara plans to update its 2026 guidance to reflect the sale of the Regulatory and Medical Writing business upon transaction close.
Perella Weinberg Partners LP served as the financial advisor, and Troutman Pepper Locke LLP served as legal counsel to Certara. Guggenheim Securities, LLC served as the financial advisor, and McDermott Will & Schulte served as legal counsel to Veristat.
About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit us at www.certara.com.
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s plans to sell its Regulatory and Medical Writing business, the expected timetable for completing the transaction, the expected use of proceeds from the transaction and the future financial and operating performance of the company following the transaction. Actual results could differ materially from those in the forward-looking statements due to, among other things, the possibility that the transaction does not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the transaction; customer and shareholder reaction to the transaction; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; changes in general and international economic conditions; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the company with the Securities and Exchange Commission on February 26, 2026, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
Pan Communications
certara@pancomm.com
